Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
27 sept. 2023 16h30 HE
|
Cellectis Inc.
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Societal CDMO to Participate in RBC Capital Markets Virtual CDMO Conference
25 sept. 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO)...
Societal CDMO Announces Corporate Restructuring
20 sept. 2023 16h05 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASDAQ: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
Culture Biosciences Appoints Darcy Birse as Chief Commercial Officer
13 sept. 2023 06h53 HE
|
Culture Biosciences
South San Francisco, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences, a leading provider of innovative, future-forward bioprocessing solutions, is pleased to announce the appointment of Darcy...
Novotech Releases Comprehensive Global Landscape Report on Gallbladder Cancer Clinical Trials
07 sept. 2023 17h49 HE
|
Novotech
BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest specialist clinical trial report...
Novotech Publishes Nasopharyngeal Carcinoma Global Clinical Trial Landscape Report
07 sept. 2023 17h49 HE
|
Novotech
BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest specialist clinical trial report –...
Societal CDMO Secures Project Expansion Agreements With Several Existing Customers
07 sept. 2023 07h00 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to...
NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M
06 sept. 2023 08h30 HE
|
NurExone Biologic Inc
TORONTO and HAIFA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing...
Monthly information on share capital and company voting rights
05 sept. 2023 16h30 HE
|
Cellectis Inc.
PARIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of...
Societal CDMO Announces Pricing of $8.3 Million Public Offering of Common Stock
24 août 2023 07h30 HE
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal”; NASDAQ: SCTL), a contract development and manufacturing organization (“CDMO”) dedicated to solving...